Al Topin, TOPIN & ASSOCIATES
Unless the brand is bleeding money, it's time to have a serious face-to-face discussion on staying the course
Al Topin
PRESIDENT | TOPIN & ASSOCIATES
Unless the brand is bleeding money (at which point they won't be asking what to cut, they'll be telling you), it's time to have a serious face-to-face discussion on staying the course. If you believe it is in the client's best interest to stick to their plan, then it's time to explain you can't add by subtracting—meaning it's impossible to add value to their brand by subtracting dollars from their budget. Instead, it's time to look closely for added opportunities during an economic crunch. Such as:
- Opportunity to increase share of voice without increasing expenses. Competitors may cut back; media may be open to further negotiation.
- Opportunity to fine-tune the creative and add further impact to messaging, which allows clients to shout louder and gain further awareness.
- Opportunity to shift some budget dollars into added digital tactics that can be more cost-effective, reach additional target audiences, and deliver clear measurements of effectiveness.
The key is not to add dollars to the budget, but to spend them better, without losing continuity and focus. Overall, it's time to be proactive, not reactive. And to remind your clients that short-term budget cuts do not deliver long term growth.
Al Topin
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
